Glenmark Life Sciences Ltd – Globe Capital
Glenmark Life Sciences Ltd
Closed
Price Band
Rs. 695 – 720
IPO Issue Period
Jul 27, 2021 to Jul 29, 2021
Fresh issue
Rs. 1513.60 Cr.
Face value
Rs. 2/-
Fresh issue
Rs. 1060.00 Cr.
Offer for sale
Rs. 453.60 Cr.
Minimum Shares for Retail
20 shares
Maximum Shares for Retail
260 shares
Listing on
NSE, BSE
Issue Type
Book Building
Tentative Listing Date
6-Aug-21
QIB
Not More than 50% of the offer
NII
Not less than 15% of the offer
Retail
Not less than 35% of the offer
Registrar to the Issue
KFintech Private Limited

BoA Merrill Lynch, BOB Capital Markets Limited, DAM Capital Advisors Ltd (Formerly IDFC Securities Ltd), Goldman Sachs (India) Securities Private Limited, Kotak Mahindra Capital Company Limited, SBI Capital Markets Limited

Glenmark Life Sciences is the leading manufacturer of Active Pharmaceutical Ingredients (APIs). The company develops, manufactures, and supplies high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas. It further operates in Contract Development and manufacturing operations (CDMO) to offer services to specialty Pharmaceutical companies. Its products are being sold in India and also exported to multiple countries i.e. Europe, North America, Latin America, Japan, etc. Currently, it has 4 manufacturing facilities at Ankleshwar and Dahej in Gujarat and Mohol and Kurkumbh in Maharashtra State with an aggregate annual installed capacity of 725.8 KL as of December 31, 2020. Glenmark Pharmaceuticals Limited is the promoter of the company.

For year/ period ended ( in Cr.)

31 Mar 2021 31 Mar 2020 31 Mar 2019
Total Revenue 1885.17 1537.31 886.42
Profit After Tax 351.58 313.1 195.9
EPS 32.16 29.04 24.64
OPM(%) 31.4 31.48 28
PATM(%) 18.65 20.37 22.07
  • It is a leading manufacturer of selected specialized APIs for chronic therapeutic areas like CVS, CNS, diabetes, and pain management.
  • Export products in Europe, Latin America, North America, Japan, and the rest of the world.
  • The Company has strong Relationships with Leading Global Generic Companies.
  • Proven track record of strong financial performance.
  • High-quality product manufacturing with R&D infrastructure.
  • To make payment of outstanding purchase consideration to the promoter for the spin-off of the API business from the promoter into the company.
  • To finance capital expenditure requirements.

With the strong promoter background & consistent financial performance, the company will get premium valuation in the market. Hence, investor can subscribe to the issue for the medium to long-term.

Open Account